Strategic Blueprint’s GSK GSK Stock Holding History

Strategic Blueprint’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,449	Closed	-$296K	–	509
2022 Q2	$296K	Buy	+5,449	New	+$301K	0.04%	374
2021 Q3	–	Sell	-41	Closed	-$2K	–	767
2021 Q2	$2K	Buy	+41	New	+$1.97K	﹤0.01%	1228
2020 Q3	–	Sell	-32,948	Closed	-$1.68M	–	218
2020 Q2	$1.68M	Buy	32,948 +1,530	+5%	+$78.5K	0.59%	51
2020 Q1	$1.49M	Buy	31,418 +1,997	+7%	+$107K	0.87%	42
2019 Q4	$1.73M	Sell	29,421 -961	-3%	-$53.5K	1.19%	33
2019 Q3	$1.62M	Buy	30,382 +636	+2%	+$32.7K	1.22%	30
2019 Q2	$1.49M	Buy	29,746 +5,000	+20%	+$251K	1.27%	32
2019 Q1	$1.29M	Buy	+24,746	New	+$1.24M	1.17%	32

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Strategic Blueprint's GSK Position: Q3 2022 in Review

Strategic Blueprint sold out of GSK (GSK) in Q3 2022, closing a stake of 5,449 shares — an estimated $296K sold.

Strategic Blueprint first reported a position in GSK in Q1 2019 and held it in 8 quarters. The position peaked at $1.73M in Q4 2019. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Strategic Blueprint reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Strategic Blueprint sold 5,449 GSK shares in Q3 2022, an estimated $296K.
Strategic Blueprint first reported a position in GSK in Q1 2019 and held it in 8 quarters.
Strategic Blueprint's GSK position peaked at $1.73M in Q4 2019.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Strategic Blueprint's 13F filing for Q3 2022, filed 8 Nov 2022.